問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

顏家瑞

Recruiting

List

188Cases

2020-10-26 - 2029-12-31

Phase III

Active
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)

  • Condition/Disease

    esectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)

  • Test Drug

    Durvalumab

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2022-12-01 - 2026-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-06-26 - 2026-12-31

Phase I/II

Active
A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants with HER2-Overexpressing Gastric Cancer (DESTINY-Gastric03)

  • Condition/Disease

    HER2 overexpressing locally advanced or metastatic, unresectable Gastric Cancer.

  • Test Drug

    Trastuzumab Deruxtecan

Participate Sites
6Sites

Recruiting6Sites

2023-11-01 - 2027-12-31

Phase II

Active
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2.

  • Condition/Disease

    Gastric Cancer Gastroesophageal Junction Cancer Pancreatic Adenocarcinoma

  • Test Drug

    AZD0901

Participate Sites
5Sites

Recruiting4Sites

2020-01-21 - 2024-04-08

Phase III

Completed
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-controlled Study to Compare the Efficacy and Safety of Tislelizumab (BGB-A317) Combined With Gemcitabine Plus Cisplatin Versus Placebo Combined With Gemcitabine Plus Cisplatin as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

  • Condition/Disease

    Recurrent or Metastatic Nasopharyngeal Cancer

  • Test Drug

    BGB-A317

Participate Sites
3Sites

Recruiting3Sites

2022-09-01 - 2024-12-20

Phase I

Completed
Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumor、 Non Small Cell Lung Cancer 、Head and Neck Squamous Cell Carcinoma (HNSCC) 、Nasopharyngeal Carcinoma (NPC)

  • Test Drug

    BGB-A317BGB-A445

Participate Sites
4Sites

Recruiting4Sites

2023-07-01 - 2026-01-31

Phase II

Active
A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Head and Neck Squamous Cell Carcinoma、 Head and Neck Cancer

  • Test Drug

    BGB-A317 (Tislelizumab); BGB-A425; LBL-007

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

2020-04-01 - 2026-05-01

Phase III

Active
An Open Label, Multicentre, Long-Term Extension Study of Tislelizumab- Containing Treatment and/or Pamiparib-Containing Treatment in Patients With Advanced Malignancies

  • Condition/Disease

    Advanced Malignancies

  • Test Drug

    BGB-A317 (Tislelizumab)和BGB-290 (Pamiparib)

Participate Sites
9Sites

Not yet recruiting4Sites

Recruiting3Sites

Terminated2Sites

2021-06-01 - 2025-06-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-06-01 - 2027-12-31

Phase I

Active
A Phase 1, First-in-Human, Open-label, Dose- escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 in Subjects with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    injection

Participate Sites
3Sites

Recruiting3Sites

1 2 3 4 5 19
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB